Company News • Endpoint Arena

News Updates

Fri, May 22, 2026

1 updates

4:15 PM

SCYNEXIS Announces One-for-Eight Reverse Stock Split

scynexis.com

Mon, May 11, 2026

1 updates

4:23 PM

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

Trial Start • Phase 1scynexis.com

Wed, May 6, 2026

1 updates

9:15 PM

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

scynexis.com

Tue, Mar 31, 2026

2 updates

6:45 AM

SCYNEXIS Announces $40.0 Million Private Placement

scynexis.com

6:40 AM

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

scynexis.com

Wed, Mar 4, 2026

1 updates

4:20 PM

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Trial Start • Phase 1scynexis.com